We came across a bullish thesis on Recursion Pharmaceuticals, Inc. on r/stocks by Antique-Reference585. In this article, we ...

The rise of China, the buzz around AI, challenging global market dynamics, the recent surge in dealmaking and exciting new ...

For decades, artificial intelligence advanced in careful, mostly linear steps. Researchers built models. Engineers improved performance. Organizations deployed systems to automate specific tasks. Each ...

Vampirella: Armageddon #7 hits stores Wednesday! Can the rescue party save Vampirella from Hell, or will they need rescuing ...

Nvidia is turning its AI firepower toward the hardest problems in medicine, striking multibillion-dollar alliances with ...

2026 is highlighted as the year of the singularity with Elon Musk warning of underestimated impacts; conversations with him ...

Author Shawn Peters blends clarity and rigor to make data structures and algorithms accessible to all learners. COLORADO, CO, UNITED STATES, January 2, 2026 /EINPresswire.com/ — Vibrant Publishers ...

When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

Shares of clinical-stage biotechnology company Recursion Pharmaceuticals (NASDAQ: RXRX) soared 11.43% on Wednesday, significantly outperforming the broader market. The rally followed a major analyst ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...